CA3084020C - Modified CAS9 systems to alter the genome of eukaryotes - Google Patents
Modified CAS9 systems to alter the genome of eukaryotesInfo
- Publication number
- CA3084020C CA3084020C CA3084020A CA3084020A CA3084020C CA 3084020 C CA3084020 C CA 3084020C CA 3084020 A CA3084020 A CA 3084020A CA 3084020 A CA3084020 A CA 3084020A CA 3084020 C CA3084020 C CA 3084020C
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- engineered
- protein
- cell
- cas9 protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3281020A CA3281020A1 (en) | 2018-02-15 | 2019-02-15 | Engineered cas9 systems for eukaryotic genome modification |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631304P | 2018-02-15 | 2018-02-15 | |
| US62/631,304 | 2018-02-15 | ||
| US201862720525P | 2018-08-21 | 2018-08-21 | |
| US62/720,525 | 2018-08-21 | ||
| PCT/US2019/018335 WO2019161290A1 (en) | 2018-02-15 | 2019-02-15 | Engineered cas9 systems for eukaryotic genome modification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3281020A Division CA3281020A1 (en) | 2018-02-15 | 2019-02-15 | Engineered cas9 systems for eukaryotic genome modification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3084020A1 CA3084020A1 (en) | 2019-08-22 |
| CA3084020C true CA3084020C (en) | 2025-11-25 |
Family
ID=65995829
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3084020A Active CA3084020C (en) | 2018-02-15 | 2019-02-15 | Modified CAS9 systems to alter the genome of eukaryotes |
| CA3281020A Pending CA3281020A1 (en) | 2018-02-15 | 2019-02-15 | Engineered cas9 systems for eukaryotic genome modification |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3281020A Pending CA3281020A1 (en) | 2018-02-15 | 2019-02-15 | Engineered cas9 systems for eukaryotic genome modification |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10767193B2 (https=) |
| EP (1) | EP3752607A1 (https=) |
| JP (3) | JP7109547B2 (https=) |
| KR (3) | KR102465067B1 (https=) |
| CN (1) | CN111902536B (https=) |
| AU (3) | AU2019222568B2 (https=) |
| BR (1) | BR112020010479A2 (https=) |
| CA (2) | CA3084020C (https=) |
| IL (2) | IL321024A (https=) |
| SG (1) | SG11202007382TA (https=) |
| WO (1) | WO2019161290A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| US11111492B2 (en) * | 2017-03-06 | 2021-09-07 | Florida State University Research Foundation, Inc. | Genome engineering methods using a cytosine-specific Cas9 |
| KR20210045360A (ko) | 2018-05-16 | 2021-04-26 | 신테고 코포레이션 | 가이드 rna 설계 및 사용을 위한 방법 및 시스템 |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| CA3129835A1 (en) | 2019-02-15 | 2020-08-20 | Sigma-Aldrich Co. Llc | Crispr/cas fusion proteins and systems |
| CA3130789A1 (en) | 2019-03-07 | 2020-09-10 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
| WO2021127209A1 (en) | 2019-12-17 | 2021-06-24 | Sigma-Aldrich Co. Llc | Genome editing in bacteroides |
| GB2594339B (en) * | 2020-02-14 | 2023-02-08 | Metagenomi Inc | Enzymes with RUVC domains |
| CA3163463A1 (en) * | 2020-03-11 | 2021-09-16 | Fuqiang Chen | High fidelity spcas9 nucleases for genome modification |
| GB2608292B (en) * | 2020-03-31 | 2024-02-14 | Metagenomi Inc | Class II, type II CRISPR systems |
| CN112159801B (zh) * | 2020-07-13 | 2022-11-15 | 复旦大学 | SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用 |
| EP4230737A4 (en) * | 2020-09-21 | 2024-07-24 | Korea University Research and Business Foundation | NOVEL IMPROVED BASIC EDITING OR REVISION FUSION PROTEIN AND USE THEREOF |
| JP2023549339A (ja) * | 2020-11-06 | 2023-11-24 | ペアワイズ・プランツ・サーヴィシズ，インコーポレイテッド | 対立遺伝子の、ｒｎａによりコードされるｄｎａ置換のための組成物および方法 |
| CN113717960B (zh) * | 2021-08-27 | 2023-07-18 | 电子科技大学 | 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法 |
| CA3225082A1 (en) | 2021-08-27 | 2023-03-02 | Brian C. Thomas | Enzymes with ruvc domains |
| MX2024006257A (es) | 2021-11-24 | 2024-07-29 | Metagenomi Inc | Sistemas de endonucleasas. |
| CN114657181B (zh) * | 2022-04-01 | 2023-08-25 | 安徽大学 | 一种靶向H1.4的sgRNA以及H1.4基因编辑方法 |
| CN119948064A (zh) * | 2022-09-23 | 2025-05-06 | 庄伟哲 | 靶向整合素 αIIbβ3的含组织纤维溶酶原活化剂或其变异体的融合蛋白质及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232430A1 (en) | 2001-11-26 | 2003-12-18 | Advanced Cell Technology | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| EP3241902B1 (en) * | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| EP3363902B1 (en) * | 2012-12-06 | 2019-11-27 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
| AU2013359262C1 (en) * | 2012-12-12 | 2021-05-13 | Massachusetts Institute Of Technology | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
| EP3004370B1 (en) | 2013-06-05 | 2024-08-21 | Duke University | Rna-guided gene editing and gene regulation |
| US9074199B1 (en) * | 2013-11-19 | 2015-07-07 | President And Fellows Of Harvard College | Mutant Cas9 proteins |
| JP2017503514A (ja) * | 2014-01-24 | 2017-02-02 | ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ | Ｃａｓ９ターゲッティングをガイドする配列に関する方法および組成物 |
| US11242525B2 (en) * | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
| EP3633032A3 (en) * | 2014-08-28 | 2020-07-29 | North Carolina State University | Novel cas9 proteins and guiding features for dna targeting and genome editing |
| WO2016054326A1 (en) * | 2014-10-01 | 2016-04-07 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| LT3604527T (lt) | 2016-06-02 | 2021-06-25 | Sigma-Aldrich Co., Llc | Programuojamų, dnr surišančių baltymų panaudojimas tiksliniam genomo modifikavimui pagerinti |
| US10017760B2 (en) | 2016-06-24 | 2018-07-10 | Inscripta, Inc. | Methods for generating barcoded combinatorial libraries |
| JP7305534B2 (ja) | 2016-07-06 | 2023-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛関連障害を処置するための物質及び方法 |
| JP7182545B2 (ja) * | 2016-12-14 | 2022-12-02 | ヴァーヘニンゲン ユニヴェルシテット | 熱安定性ｃａｓ９ヌクレアーゼ |
| KR102523217B1 (ko) * | 2017-07-11 | 2023-04-20 | 시그마-알드리치 컴퍼니., 엘엘씨 | 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용 |
| KR20200036912A (ko) * | 2017-07-31 | 2020-04-07 | 리플렉션 바이오테크놀러지스 리미티드 | 안과 질환을 위한 세포 모델 및 치료요법 |
-
2019
- 2019-02-15 CN CN201980013625.2A patent/CN111902536B/zh active Active
- 2019-02-15 KR KR1020207026571A patent/KR102465067B1/ko active Active
- 2019-02-15 KR KR1020227002190A patent/KR102494449B1/ko active Active
- 2019-02-15 CA CA3084020A patent/CA3084020C/en active Active
- 2019-02-15 WO PCT/US2019/018335 patent/WO2019161290A1/en not_active Ceased
- 2019-02-15 SG SG11202007382TA patent/SG11202007382TA/en unknown
- 2019-02-15 CA CA3281020A patent/CA3281020A1/en active Pending
- 2019-02-15 BR BR112020010479-5A patent/BR112020010479A2/pt unknown
- 2019-02-15 IL IL321024A patent/IL321024A/en unknown
- 2019-02-15 US US16/277,823 patent/US10767193B2/en active Active
- 2019-02-15 AU AU2019222568A patent/AU2019222568B2/en active Active
- 2019-02-15 JP JP2020531575A patent/JP7109547B2/ja active Active
- 2019-02-15 EP EP19714890.1A patent/EP3752607A1/en active Pending
- 2019-02-15 KR KR1020237003098A patent/KR102684890B1/ko active Active
- 2019-02-15 IL IL274528A patent/IL274528B2/en unknown
-
2020
- 2020-07-30 US US16/943,813 patent/US12297449B2/en active Active
-
2022
- 2022-01-11 AU AU2022200130A patent/AU2022200130B2/en active Active
- 2022-05-23 JP JP2022083820A patent/JP7559005B2/ja active Active
-
2024
- 2024-04-04 AU AU2024202158A patent/AU2024202158A1/en active Pending
- 2024-07-18 JP JP2024114477A patent/JP2024161376A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190249200A1 (en) | 2019-08-15 |
| CN111902536A (zh) | 2020-11-06 |
| US12297449B2 (en) | 2025-05-13 |
| KR102684890B1 (ko) | 2024-07-12 |
| JP7109547B2 (ja) | 2022-07-29 |
| EP3752607A1 (en) | 2020-12-23 |
| KR102465067B1 (ko) | 2022-11-10 |
| KR20230022258A (ko) | 2023-02-14 |
| AU2024202158A1 (en) | 2024-05-02 |
| BR112020010479A2 (pt) | 2020-11-24 |
| CA3084020A1 (en) | 2019-08-22 |
| AU2019222568B2 (en) | 2021-10-14 |
| JP2021505180A (ja) | 2021-02-18 |
| AU2019222568A1 (en) | 2020-05-21 |
| SG11202007382TA (en) | 2020-08-28 |
| JP2022122910A (ja) | 2022-08-23 |
| CN111902536B (zh) | 2024-07-30 |
| KR102494449B1 (ko) | 2023-01-31 |
| IL274528B1 (en) | 2025-06-01 |
| US10767193B2 (en) | 2020-09-08 |
| IL321024A (en) | 2025-07-01 |
| IL274528B2 (en) | 2025-10-01 |
| KR20220015502A (ko) | 2022-02-08 |
| US20200354752A1 (en) | 2020-11-12 |
| AU2022200130B2 (en) | 2024-03-07 |
| CA3281020A1 (en) | 2026-03-02 |
| JP7559005B2 (ja) | 2024-10-01 |
| IL274528A (en) | 2020-06-30 |
| KR20200121342A (ko) | 2020-10-23 |
| AU2022200130A1 (en) | 2022-02-10 |
| WO2019161290A1 (en) | 2019-08-22 |
| JP2024161376A (ja) | 2024-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3084020C (en) | Modified CAS9 systems to alter the genome of eukaryotes | |
| KR102655021B1 (ko) | 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용 | |
| KR102458395B1 (ko) | 프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선 | |
| US20230287377A1 (en) | Crispr/cas fusion proteins and systems | |
| CA3066798A1 (en) | Synthetic guide rna for crispr/cas activator systems | |
| HK40040051B (zh) | 用於真核基因组修饰的改造的cas9系统 | |
| BR122025004697A2 (pt) | Sistema para modificar uma sequência cromossômica em uma célula eucariótica, pluralidade de ácidos nucleicos, vetor, célula eucariótica, proteína de fusão, composição e usos | |
| BR122025004697B1 (pt) | Sistemas para modificar um genoma eucariótico, pluralidade de ácidos nucleicos, vetor, e proteína de fusão | |
| HK40040051A (en) | Engineered cas9 systems for eukaryotic genome modification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200528 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED Effective date: 20250326 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250326 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250326 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20250725 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250811 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250811 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20251120 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20251125 |